Several new drugs are expected to potentially reshape treatment options in 2026, with some outlets highlighting specific medications such as Zongertinib and Sevabertinib for certain types of cancer. Other reports mention potential breakthroughs in treating ovarian cancer, suicide risk, and intermediate dry AMD, among other conditions. The impact of these developments on the pharmaceutical industry and healthcare landscape is still taking shape.